Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    An Enquiry

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.https://marketing.lgmpharma.com/LGM-CDMO

    Virtual Booth

    Contact Supplier

    Vamsi Labs is one of the major manufacturers of Anti-asthmatic, Anti-migraine & Anti-psychotic APIs.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    An Enquiry

    Menu

    Ropeginterferon ALFA-2B

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Pharmaessentia To Build U.S. Plant In Puerto Rico For Besremi®
    Pharmaessentia To Build U.S. Plant In Puerto Rico For Besremi®

    09 Feb 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-02-09/pharmaessentia-announces-plans-to-establish-new-us-manufacturing-facility-in-puerto-rico-to-suppor

    PHARMIWEB
    09 Feb 2026
    Share Share
    PharmaEssentia’s BESREMi Added to Guidelines for Thrombocythemia
    PharmaEssentia’s BESREMi Added to Guidelines for Thrombocythemia

    27 Jan 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260127377586/en/PharmaEssentia-Announces-Updated-NCCN-Clinical-Practice-Guidelines-Include-ropeginterferon-alfa-2b-njft-BESREMi-for-Treatment-of-Essential-Thrombocythemia-ET

    BUSINESSWIRE
    27 Jan 2026
    Share Share
    FDA Sets August 30, 2026 PDUFA Goal Date For Ropeginterferon
    FDA Sets August 30, 2026 PDUFA Goal Date For Ropeginterferon

    13 Jan 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-01-13/fda-confirms-a-pdufa-goal-date-of-august-30-2026-for-the-sbla-submission-of-ropeginterferon-alfa-2b

    PHARMIWEB
    13 Jan 2026
    Share Share
    PharmaEssentia Reports Positive Phase 2b ET Study Data
    PharmaEssentia Reports Positive Phase 2b ET Study Data

    12 Jan 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-01-12/pharmaessentia-announces-positive-topline-phase-2b-data-from-exceed-et-study-evaluating-ropeginterfe

    PHARMIWEB
    12 Jan 2026
    Share Share
    AOP Health Unveils Hemato-Oncology Trial Results At ASH Congress
    AOP Health Unveils Hemato-Oncology Trial Results At ASH Congress

    07 Dec 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251207587915/en/Hemato-Oncology-Trials-AOP-Health-Presents-New-Results-at-Top-Congress-ASH

    BUSINESSWIRE
    07 Dec 2025
    Share Share
    PharmaEssentia's Phase 3 SURPASS-ET Trial Published in The Lancet
    PharmaEssentia's Phase 3 SURPASS-ET Trial Published in The Lancet

    24 Nov 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251124044530/en/PharmaEssentia-Announces-Publication-of-Phase-3-SURPASS-ET-Results-in-The-Lancet-Haematology

    BUSINESSWIRE
    24 Nov 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.